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INTRODUCTION:  We  present  a case  of wound  dehiscence  in  a patient with  clinical  features  of herpes
zoster.
PRESENTATION  OF  CASE:  A  44  year  old  woman,  with  a history  of  recurrent  herpes  zoster  infection,  pre-
sented  to the  accident  and  emergency  department  with the  extrusion  of  a left  sided tear-drop  shaped
euro-silicone  breast  implant  from  an  old surgical  scar.  A month  prior  to admission,  this  patient  had  devel-
oped  unilateral  crops  of  vesicles  along  the  surgical  scar which  was  apposing  her  left infra-mammary  fold.
This was preceded  by  fatigue  and  neuralgia.  Histology  revealed  acute  inﬂammation  related  to  a  probable
Herpesviridae  infection.
DISCUSSION:  In  this  report  we  discuss  the ﬁrst  case  of  a viral  infection  predisposing  to  a wound  dehiscence
occurring  in an  old  surgical  scar.
CONCLUSION:  This  case  report  illustrates  the  real  but  rare  possibility  of recurrent  herpes  zoster  causing
gradual  thinning  of  an  old  surgical  scar.  This  resulted  in an  extrusion  of  the  underlying  breast  implant.
© 2015  The  Authors.  Published  by Elsevier  Ltd.  on behalf  of  Surgical  Associates  Ltd.  This  is  an  open
he  CCaccess  article  under  t
. Introduction
Herpes zoster is a medical condition caused by the reactivation
f varicella zoster virus (VZV). It typically affects older people who
re immunocompromised and is associated with well documented
omplications. These include post herpetic neuralgia, secondary
acterial infection and ophthalmological sequelae. We  discuss the
ase of a female patient with a history of recurrent herpes zoster
ho developed the classic vesicular rash over the dermatome
hich incorporated a surgical scar. This subsequently resulted in
ound dehiscence and extrusion of the underlying breast implant.
o our knowledge this is the ﬁrst reported case of this complication.
e believe that this case report will add to our understanding of
ate surgical site infection and potential complications associated
ith herpesviridae infections.
. Case presentation
A 44 year old woman presented to the accident and emer-
ency department and was found to have extrusion of a left breast
ear shaped implant through an old infra-mammary surgical scar.
he patient had undergone an equalization breast augmentation 8
ears ago in Prague. A month prior to her presentation, she had
eveloped a recurrent attack of herpes zoster involving the left
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breast infra-mammary fold. This resulted in the formation of vesi-
cles within the surgical scar, followed by a gradual thinning of the
overlying skin. Two  areas of skin subsequently broke down initially
causing a serosanguinous discharge. Complete dehiscence of the
scar occurred despite taking acyclovir since the start of the her-
pes zoster. She had a number of comorbidities, including maturity
onset diabetes of the young (MODY), ﬁbromyalgia, and recurrent
episodes of herpes zoster. Despite being vaccinated for the lat-
ter condition, she experienced an average of three episodes of
relapse per year. She had also been placed on a suppressive dose
of valacyclovir by the consultant clinical immunologist. This had
initially resulted in a decrease in the frequency of attacks. How-
ever, the episodes had increased over the last 12 months. These
acute relapses were treated with acyclovir. To date no cause for the
recurrences has been identiﬁed.
On examination of the breasts, an eight centimeter wound was
noted within the left infra-mammary fold, which was erythema-
tous, tender and associated with purulent discharge (Fig. 1). The
implant was  clearly visible, extruding through the old scar. It
was encased in a calciﬁed coating (Fig. 1). Blood tests revealed
raised inﬂammatory markers. A moderate growth of staphylococ-
cus aureus was found on the wound culture.
Given the extent of this protrusion, the patient was promptly
transferred to the care of the breast team. She underwent surgery
to remove the implant. This procedure involved removal of the
implant from its sub-glandular position, saline irrigation of the
cavity, and excision of the skin infected with the herpes zoster
(Fig. 2). The skin was closed with interrupted mattress prolene
sutures which were removed 10 days later. Post-operative histol-
iates Ltd. This is an open access article under the CC BY-NC-ND license (http://
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Fig. 1. Extrusion of the implant.
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aFig. 2. Implant after removal.
gy of the excised skin cited: ‘extensive inﬂammation of the skin
nd subcutaneous tissue with ulceration probably related to herpes
oster’.
Post-operatively, the patient was commenced on a course of
nti-viral medication and antibiotics. She was placed under regular
ollow up with the breast team. Unfortunately, eight months later,
he patient attended the breast care unit with a similar presentation
ffecting the contralateral breast implant. The right breast implant
as also removed surgically. She has since been discharged as she
xperienced no further problems.
. Discussion
This report presents the ﬁrst documented case of a breast
rosthesis extrusion and wound dehiscence as a complication of
epeated herpes zoster infection. In this case, herpesviridae is
mplicated. The patient’s past history and clinical features suggest
erpes zoster [1].
The risk of dehiscence of a wound is affected by a number of
actors including infection, hematoma formation, or poor surgi-
al technique [2]. It is compounded by several risk factors such
s smoking, prolonged steroid use and age [2]. Interestingly, there
re a number of publications outlining a causal relation betweenPEN  ACCESS
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herpes simplex virus and post-operative infection. Herpes simplex
virus has been identiﬁed in a total hip arthroscopy [3] and free
radial forearm ﬂap site [4]. To date, there are no reported cases of
this phenomenon occurring in well healed scars or in association
with herpes zoster. The only previously reported cases alluding to
scar involvement in herpes zoster is that of cutaneous sarcoidosis
inﬁltrating healed vesicular scars [5].
Herpes zoster is a condition caused by the reactivation of vari-
cella zoster virus. The incidence worldwide is 1.2–3.4/1000. Long
term population studies suggest this infection is likely to increase
to 3.9–11.8/1000 in patients over the age of 65 year [6,7]. Herpes
zoster typically presents with non-speciﬁc prodromal symptoms
of burning, itching or paresthesia followed by a vesicular rash con-
ﬁned to a speciﬁc unilateral dermatome.
It is interesting in this case that despite being thoroughly inves-
tigated by her clinical Immunologist, no identiﬁable cause could
be identiﬁed as a reason for her having recurrent attacks of her-
pes zoster. There is a possibility that her co-morbidities could have
predisposed her to an increased risk of recurrence and wound
breakdown. It is well understood that the incidence of herpes zoster
increases with both age and in immunocompromised states [1,6].
A study by Rimland and Moanna [8] suggested that there is an
increase in the incidence of herpes zoster beyond the age of 40
years [8]. Additionally, a history of diabetes has been associated
with an increased incidence of herpes zoster [9], this is associated
with reduced levels of varicella zoster virus-speciﬁc cell mediated
immunity [10]. Furthermore, diabetes is a known predisposing fac-
tor for infection [11]. Thus, diabetes may  have contributed to both
herpes zoster recurrence and a higher incidence of complications.
Finally, the presence of a breast prosthesis carries with it a real
though low risk of secondary infection. In an observational study
looking at 10,941 patients with breast implants, it was  observed
that infection rates were 0.8%. A number of cases occurred months
and even years later. It was  noted that these cases were associated
with distant foci of infection [12].These ﬁndings suggest that there
is beneﬁt in the early detection and prompt treatment of patients
with breast prostheses who  develop infections with a potential for
haematogenous spread.
This leads us to question whether extra vigilance is needed for
recurrent herpes zoster in this population. In the acute setting, her-
pes zoster treatment is reserved for immunocompromised patients,
non-immunocompromised patients who  are over the age of 50 and
those having severe manifestations or complications of the disease
[13]. The main stay of treatment is with oral antivirals and analge-
sia, but there is no consensus for the use of steroids, opioids, NSAIDs
and tricyclic antidepressants in managing the complications; this
is particularly in the elderly [13].
At present, strategies for the prevention of both ﬁrst and recur-
rent episodes of herpes zoster remain unclear. Currently, there
is evidence to support the use of a zoster vaccine (zostavax)
in preventing these attacks in the elderly population [14,15]. In
2008, the Advisory Committee on Immunization Practice (ACIP)
recommended the use of zostavax in patients aged 60 and
older [14]. The Food and Drug Administration (FDA) extended
this guideline in 2011 to include patients aged 50 years or
older [16,17]. ACIP, however, have not supported this and main-
tain the use of zostavax for patients aged 60 years or older
only [16]. In our case report, our 44 years old patient had
received the varicella zoster vaccine and yet recurrences were
not prevented. This could have been related to her age or her
co-morbidities.
This case highlights a need for more research to be
conducted regarding strategies to prevent herpes zoster recur-
rence in predisposed individuals, especially in the younger
population.
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. Conclusion
The case demonstrates the real but rare risk of herpes zoster
nfection of the dermatome of a scar above a prosthesis resulting
n dehiscence and subsequent extrusion of the breast implant.
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